Absence of aberrant myeloid progenitors by flow cytometry is associated with favorable response to azacitidine in higher risk myelodysplastic syndromes.

Alhan, Canan

Absence of aberrant myeloid progenitors by flow cytometry is associated with favorable response to azacitidine in higher risk myelodysplastic syndromes. [electronic resource] - Cytometry. Part B, Clinical cytometry May 2014 - 207-15 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

1552-4957

10.1002/cyto.b.21160 doi


Aged
Aged, 80 and over
Antimetabolites, Antineoplastic--therapeutic use
Azacitidine--therapeutic use
Biomarkers, Pharmacological--analysis
Bone Marrow Cells--classification
Female
Flow Cytometry
Humans
Immunophenotyping
Leukemia, Myeloid, Acute--drug therapy
Leukemia, Myelomonocytic, Chronic--drug therapy
Male
Middle Aged
Myelodysplastic Syndromes--drug therapy
Myeloid Progenitor Cells--classification
Prognosis
Research Design
Retrospective Studies
Risk Factors